Skip to main content
. 2021 Sep 9;7(3):92–97. doi: 10.1016/j.afos.2021.09.001

Table 2.

Treatment continuation patient numbers among those who agreed to start treatment.

Drug chosen Bone status Start 6th month 12th month
Raloxifene Osteoporosis 31 16 (51.6%) 14 (45.2%)
Alendronate Osteoporosis 155 99 (63.9%) 91 (58.7%)
Alendronate Osteopenia, high risk 72 35 (48.6%) 28 (38.9%)
Denosumab Osteoporosis 5 5 (100%) 5 (100%)